NCT04051307View on ClinicalTrials.gov

Dual Vaccine Trial in Myeloproliferative Neoplasms

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 10, 2019

Primary Completion Date

July 10, 2022

Study Completion Date

July 10, 2022

Conditions
Polycythemia VeraEssential Thrombocythemia
Interventions
DRUG

PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL

Peptide vaccination

DRUG

Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL

Peptide vaccination

Trial Locations (2)

2730

Herlev Hospital, Herlev

National Center for Cancer Immune Therapy (CCIT-DK), Herlev

All Listed Sponsors
lead

Inge Marie Svane

OTHER

NCT04051307 - Dual Vaccine Trial in Myeloproliferative Neoplasms | Biotech Hunter | Biotech Hunter